InModeSTU:154 -0.47%79 EBITDA Margin % is 12.47% as of Mar. 2026, which is 65% below its 10-year median of 35.54. GuruFocus rates STU:154 with a GF Score™ of 79/100 and a GF Value™ of €16.88 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, InMode ranks better than 78.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. InMode's EBITDA for the
three
months ended in Mar. 2026 was €8.9 Mil. InMode's Revenue for the
three
months ended in Mar. 2026 was €70.9 Mil. Therefore, InMode's EBITDA margin for the quarter that ended in Mar. 2026 was 12.47%.
InMode (STU:154) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
InMode EBITDA Margin % Related Terms
InMode EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for InMode's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:154 vs QDEL, AVR, SSII: EBITDA Margin % Comparison
For the Medical Devices subindustry, InMode's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMode EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InMode's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where InMode's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMode (STU:154) has a EBITDA Margin % of 12.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InMode and its competitors. This is 65% below median its historical median of 35.54. Over the past decade, InMode's EBITDA Margin % has ranged from 17.12 to 46.98. According to the industry distribution chart, InMode ranks #176 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 21.6%.
Is InMode's EBITDA Margin % too high?
InMode's current EBITDA Margin % of 12.47% is 65% below median its 10-year median of 35.54. Over the past 10 years, this metric has ranged from a low of 17.12 to a high of 46.98. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. InMode's value of 12.47% is 66.8% above this industry median. Based on the distribution chart, InMode ranks #176 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InMode has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does InMode's EBITDA Margin % compare to QDEL and AVR?
According to the Medical Devices & Instruments industry distribution chart, InMode ranks #176 out of 816 companies for EBITDA Margin %. This places InMode in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. InMode's value of 12.47% is 66.8% above this benchmark. Historically, InMode's own EBITDA Margin % has ranged from 17.12 to 46.98 over the past decade. While the company's 10-year median is 35.54 vs. the industry median of 7.48, InMode has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InMode's current EBITDA Margin % of 12.47% is 66.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InMode and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMode's current EBITDA Margin % is 12.47%, which is 65% below median its own 10-year median of 35.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMode stock overvalued right now?
Based on GuruFocus' analysis, InMode (STU:154) is currently considered Significantly Undervalued. The stock's GF Value™ is €16.88, compared to a current price of €11.62 — trading 31.2% below its estimated fair value. The current EBITDA Margin % is 12.47%, which is 65% below median its 10-year median of 35.54 and 66.8% above the Medical Devices & Instruments industry median of 7.48. InMode's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For InMode (STU:154), the current EBITDA Margin % is 12.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMode (STU:154) Overvalued in 2026?
Based on GuruFocus' analysis, InMode stock appears to be undervalued.
The current stock price of €11.62 is trading 31.2% below its estimated GF Value™ of €16.88.
GuruFocus considers InMode to be Significantly Undervalued.
Key valuation signals for STU:154:
EBITDA Margin %: 12.47% (65% below median its 10-year median of 35.54)
GF Value™: €16.88 vs. price of €11.62 (31.2% below fair value)
Industry Position: 66.8% above the Medical Devices & Instruments median (#176 of 816)
No single metric tells the full story. See the STU:154 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
79GF Score
Get the complete analysis for STU:154
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:154 has been successfully added to your 
